Some are worried the Fed will announce that it’s going to stop -- or at least slow -- its stimulative bond-buying program. Others are worried the buying will continue. But it’s not solely inflation they’re worried about. Next, tech companies are taking ownership – and therefore control – of everything from the cloud to so-called dark fibers. Finally, GlaxoSmithKline says it will stop paying doctors to push its drugs and will stop rewarding its sales reps to push doctors to push their drugs. But just what is this “sales rep” and what is her or his role?
Some are worried the Fed will announce that it’s going to stop — or at least slow — its stimulative bond-buying program. Others are worried the buying will continue. But it’s not solely inflation they’re worried about. Next, tech companies are taking ownership – and therefore control – of everything from the cloud to so-called dark fibers. Finally, GlaxoSmithKline says it will stop paying doctors to push its drugs and will stop rewarding its sales reps to push doctors to push their drugs. But just what is this “sales rep” and what is her or his role?
